Getagraph.com logo
S&P 500
(0.34%) 5 117.54 points
Dow Jones
(0.34%) 38 369 points
Nasdaq
(0.40%) 15 991 points
Oil
(-0.98%) $83.03
Gas
(5.51%) $2.03
Gold
(0.34%) $2 355.20
Silver
(0.46%) $27.66
Platinum
(4.07%) $959.60
USD/EUR
(-0.26%) $0.932
USD/NOK
(-0.42%) $10.98
USD/GBP
(-0.56%) $0.796
USD/RUB
(1.66%) $93.40

リアルタイムの更新： Alector Inc [ALEC]

取引所: NASDAQ セクター: Healthcare 産業: Biotechnology
Upcoming Earnings Alert

3 days till quarter result
(bmo 2024-05-02)

Expected move: +/- 7.16%

BUY
60.00%
return 3.38%
SELL
25.00%
return 0.67%
最終更新日時30 4月 2024 @ 01:44
25% discount on Stockinvest.us - Use code: Podcast

2.67% $ 5.39

売る 109197 min ago

@ $6.07

発行日: 14 2月 2024 @ 05:46

リターン: -11.20%

前回のシグナル: 2月 13 - 23:30

前回のシグナル: 買う

リターン: -2.10 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:44):

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases...

Stats
本日の出来高 83 726.00
平均出来高 685 738
時価総額 516.09M
EPS $0 ( 2024-02-27 )
次の収益日 ( $-0.480 ) 2024-05-02
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -3.46
ATR14 $0.0100 (0.19%)
Insider Trading
Date Person Action Amount type
2024-03-19 Altmeyer Mark Buy 41 250 Common Stock
2024-03-19 Altmeyer Mark Buy 19 420 Stock Option (right to buy)
2024-03-19 Desouza Errol B Buy 41 250 Common Stock
2024-03-19 Desouza Errol B Buy 19 420 Stock Option (right to buy)
2024-03-19 Altmeyer Mark Sell 0 No securities of the Issuer are beneficially owned.
INSIDER POWER
-15.54
Last 100 transactions
Buy: 2 733 277 | Sell: 3 561 219

ボリューム 相関

長: -0.36 (neutral)
短: 0.52 (weak)
Signal:(54.287) Neutral

Alector Inc 相関

10 最も正の相関
UEIC0.946
INGN0.946
SPTN0.942
NKTR0.94
SSP0.938
TUEM0.931
AADI0.931
MQ0.929
GBNH0.928
BAND0.927
10 最も負の相関
XLRN-0.935
ALR-0.917
ORTX-0.917
FLMN-0.917
CPTA-0.916
TYHT-0.911
HILS-0.91
MYRG-0.909
INOD-0.909
RESN-0.906

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Alector Inc 相関 - 通貨/商品

The country flag 0.64
( weak )
The country flag 0.62
( weak )
The country flag 0.00
( neutral )
The country flag 0.46
( neutral )
The country flag 0.00
( neutral )
The country flag -0.75
( moderate negative )

Alector Inc 財務諸表

Annual 2023
収益: $97.06M
総利益: $88.21M (90.88 %)
EPS: $-1.560
FY 2023
収益: $97.06M
総利益: $88.21M (90.88 %)
EPS: $-1.560
FY 2022
収益: $133.62M
総利益: $125.15M (93.66 %)
EPS: $-1.620
FY 2021
収益: $207.09M
総利益: $0.00 (0.00 %)
EPS: $-0.467

Financial Reports:

No articles found.

Alector Inc

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease; and AL003, which is in Phase I clinical trial for the treatment of Alzheimer's disease. In addition, its products in development stage include AL044 that targets MS4A4A, a risk gene for Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

について ライブシグナル

このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。